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Abstract
Background: Graft-versus-host-disease (GVHD) is one of the rare
complications following liver transplantation. We report on the efficacy and
safety of extracorporeal photopheresis (ECP) in managing GVHD and hemophagocytic lymphohistiocytosis (HLH) after liver transplantation.
Case Report: The patient is a 63-year-old male with hepatitis B cirrhosis who
underwent liver transplantation. Three weeks after transplant, he presented
with fever, diarrhea, and poor appetite. The patient also had bilateral blanchable erythematous patches on his palms, biopsy of which was suggestive of
GVHD. The patient continued to have high-grade fever with altered mental
status. CBC showed pancytopenia. Liver function examination was normal.
Patient was started on methylprednisolone. Additional laboratory analysis
showed high ferritin (>15000 ug/L), triglycerides (280 mg/dl), and low fibrinogen (80 mg/dl). Chimerism analysis using short tandem repeat (STR) PCR confirmed the diagnosis of GVHD. Marrow biopsy showed hemophagocytosis. The
patient fulfilled the HLH-2004 diagnostic criteria. He was kept on tacrolimus
and steroids and was started on etanercept and ECP. After the first two cycles
of ECP (one cycle defined as the weekly two procedures of ECP), the patient
reported improvement of symptoms. He tolerated ECP well. His labs improved
during the course of treatment, until his peripheral blood STR showed 100%
recipient DNA. He was discharged after the fourth cycle of ECP to receive the
remaining treatments as outpatient. At one year follow-up, the patient is
asymptomatic with no evidence of GVHD or HLH.
Discussion: ECP in combination with immunosuppressive therapy and etanercept was safe and efficient in managing GVHD and HLH following liver
transplantation.
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1 | INTRODUCTION
Graft-versus-host-disease (GVHD) is one of the rare complications following liver transplantation. The disease is
due to the immune response mediated by the immunocompetent T cells from the donor liver against the immunocompromised recipient.1 The most common symptoms
of GVHD are fever, rash, and diarrhea.2 Based on the
extent of involvement of target organs, the disease is clinically divided into four grades, with grade 3 and grade
4 considered severe.2 Despite advancement in managing
these patients, the prognosis of high grade GVHD
remains dismal.2 Hemophagocytic lymphohistiocytosis
(HLH) is a rare clinical syndrome characterized by the
activation of the mononuclear phagocytic system. The
diagnosis of HLH in adults is challenging as it resembles
many disease entities such as sepsis, multiorgan failure,
and systemic inflammatory response syndrome.3 Prognosis of adult HLH is poor even with treatment with an
overall mortality reaching 75%.3
Extracorporeal photopheresis (ECP) works through ex
vivo treatment of T lymphocytes, leading to apoptosis of
these cells and change in immune response. According to
the American Society for Apheresis (ASFA) 2019 guidelines, plasmapheresis, not ECP, is category III indication
in managing HLH; the role of ECP in GVHD following
solid organ transplant has not been defined.4 Here, we
report a case of GVHD and HLH complicating liver transplantation. Our report showed the efficacy and safety of
ECP in managing GVHD and HLH after liver transplantation; a favorable outcome was achieved despite the
known poor prognosis of both GVHD and HLH. To the
best of our knowledge, there are no published reports on
ECP in this setting.
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thymocyte globulin (ATG) for induction, and tacrolimus,
mycophenolate mofetil (MMF), and methylprednisolone
for maintenance. Patient also received valganciclovir, fluconazole, and trimethoprim/sulfamethoxazole for CMV,
fungal and pneumocystis pneumonia prophylaxis. All
transfused cellular blood components were leukoreduced
and irradiated. His HBV surface antigen became negative
and surface antibody became positive two weeks following
liver transplantation.
Three weeks following transplant, the patient presented
with fever up to 104 deg F with associated fatigue, diarrhea,
and poor appetite. In addition, the patient had bilateral
blanchable erythematous patches on palmar surfaces, along
with non-tender periungual erythema on both fingers and
toes. He was worked up for viral and parasitic infections.
Palmer skin biopsy was suggestive of GVHD. Clinically the
patient continued to have high-grade fever with altered
mental status. His peripheral CBC showed pancytopenia:
WBC 0.5 K/ul, ANC 0.33 K/ul, Hgb 9.2 mg/dl, platelet
73 K/ul. Liver function examination was normal. He was
started on methylprednisolone 2 mg/kg/day. Additional
labs showed elevated ferritin (>15,000 ng/mL), triglycerides
(280 mg/dl), and low fibrinogen (80 mg/dl). CT scan of
chest, abdomen, and pelvis was negative for organomegaly
or malignancy. Marrow cytogenetic analysis showed normal
male karyotype. Chimerism analysis to detect donor DNA
using short tandem repeat (STR) PCR performed on cerebrospinal fluid, peripheral blood, and marrow showed 29%
donor DNA and 71% recipient DNA, 39% donor DNA and
61% recipient DNA, and 15% donor DNA and 85% recipient
DNA, respectively, confirming the diagnosis of GVHD.
Marrow biopsy showed slightly hypocellular marrow (30%
of cellularity) with mildly decreased erythroid, granulocytic
hematopoiesis, and hemophagocytosis (Figure 1). There
was no evidence of dysplasia or lymphoproliferative disorder. The patient fulfilled the HLH-2004 diagnostic criteria.5

2 | CASE PRESENTATION
The patient was a 63-year-old Asian male who presented
with fever and skin rash. His past medical history was
significant for type II diabetes mellitus, hypertension,
and hepatitis B cirrhosis. For the management of chronic
hepatitis B infection, the patient had been on entecavir
antiviral therapy since 2013. He had been monitored for
HBV DNA level which was negative since 2013. However, he consistently had positive HBV surface antigen
and negative HBV surface antibody. Because of his
hepatic encephalopathy symptoms, he was listed for liver
transplantation and received an orthotopic liver transplant from a deceased male donor in June 2021.
The patient postoperative course was complicated by a
subcapsular hematoma that required surgical evacuation.
The immunosuppression regimen consisted of rabbit anti-

F I G U R E 1 Morphology of marrow aspirate smear showing
hemophagocytosis (arrow) (Wright's stain, 400) [Color figure can
be viewed at wileyonlinelibrary.com]

15372995, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/trf.17096 by Henry Ford Health System, Wiley Online Library on [13/10/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

2

3

F I G U R E 2 Selected
laboratory values during
patient's treatment for GVHD
and HLH. ANC, absolute
neutrophil count; ECP,
extracorporeal photopheresis;
STR, short tandem repeat [Color
figure can be viewed at
wileyonlinelibrary.com]

Patient was kept on tacrolimus and methylprednisolone. For the treatment of GVHD, he was started on IV
solumedrol 2 mg/kg every 24 h; MMF was held due to
CMV infection. He was also started on 25 mg etanercept
(twice weekly for 4 weeks) and ECP 1 week after presentation. HLH-specific chemotherapy (etoposide and intrathecal methotrexate) was on hold due to its high risk, as
also the patient was already on steroids and ECP which
could target HLH. The Transfusion Medicine service used
the photopheresis protocol followed in managing GVHD
after allogeneic stem cell transplantation: two procedures
weekly on two consecutive days for 4 weeks, followed by
two procedures biweekly for four times, and then two
procedures monthly for four times (total of 24 procedures). Using the Therakos® Cellex® photopheresis system (Therakos Inc., West Chester, PA, USA), 1500 ml of
whole blood was processed, and UV-A light was delivered to the collected mononuclear cells after adding
methoxsalen (Uvadex). Anticoagulation consisted of acid
citrate dextrose solution A (ACD-A). Heparin was not
used due to patient's thrombocytopenia.
After the first two cycles of ECP (one cycle defined as
the weekly two procedures of ECP), the patient reported
improvement of his symptoms. He became afebrile and
his palmer erythema shrunk. He tolerated ECP well. His
labs showed improvement during the course of treatment (Figure 2), until his peripheral blood STR showed
100% recipient DNA (serum STR showed non-detectable
donor DNA). The patient was discharged after the fourth
cycle of ECP with a right subclavian tunneled catheter
and he received the remaining ECP treatment with good
tolerance as outpatient. At one year follow-up, the
patient is asymptomatic with no evidence of GVHD or
HLH. He is maintained on tacrolimus and low dose
steroids.

3 | DISCUSSION
GVHD is a multisystem disease that results when donor
T lymphocyte recognize tissues from the recipient (host)
and cause organ damage. The implicated cells include
regulatory T cells and dendritic cells from a transplanted
blood or marrow graft, or solid organ.1,6 GVHD usually
affects the skin, gastrointestinal tract, liver, and less frequently the lungs and central nervous system. GVHD has
been well-described in allogeneic hematopoietic cell
transplantation recipients; it rarely occurs following solid
organ transplantation and is often rapidly fatal.2 Acute
GVHD following liver transplantation typically presents
1–8 weeks after transplantation, and it manifests with
fever, rash, diarrhea, pancytopenia, and liver failure.2
Recipient's age greater than 50 years and hepatocellular
carcinoma have been reported as risk factors for GVHD
following liver transplantation.7 Other identified risks
factors include recipients with alcoholic liver disease,
autoimmune hepatitis, glucose intolerance,8 young
donors and recipient-donor age difference of >20 years.9
Prognosis is poor with a reported 6-month mortality rate
of 73%.10 Death often results from sepsis, bleeding, and
multiorgan failure.2,7 Although clinical symptoms and
laboratory findings are nonspecific, histologic tissue
examination can give a clue to the diagnosis. Chimerism
analysis of recipient tissues to detect donor DNA using
STR loci is considered diagnostic in a patient with compatible clinical and histological features of GVHD.11 Our
patient presented with fever, rash, and diarrhea 3 weeks
following orthotopic liver transplantation. Palmer skin
biopsy was suggestive of GVHD. Chimerism analysis
using STR PCR performed on patient's cerebrospinal
fluid, peripheral blood, and marrow revealed donor
DNA, thus confirming the diagnosis of GVHD.
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Photopheresis use has been reported in GVHD following solid organ transplantation. In a review of
28 reports on GVHD in pediatric solid organ transplantation published between 1990 and 2015, ECP was used in
only one case of a 7-year-old boy who developed GVHD
following multivisceral organ transplantation.12 GVHD
was unresponsive to steroids, multiple immunosuppressive agents, biologics, in addition to ECP. In adults, ECP
use has been reported in GVHD with good outcomes following multivisceral organ transplantation,13 liver
transplantation,14 and simultaneous pancreas-kidney
transplantation.15 Houston et al reported the use of ECP
in a 28-year-old man on Days 62 and 67 post multivisceral organ transplantation with reduction in chimerism
over 9 days; however, the patient died of sepsis on Day
73.16 Worel and colleagues provided ECP to a 52-year-old
female starting Day 70 after lung transplantation; the
patient had refractory chimerism and died on Day
99 from multi-organ failure.17
Our patient's clinical course was complicated by the
development of HLH, as he fulfilled the HLH-2004 diagnostic criteria.5 HLH is a syndrome of defective cytotoxic
cell control and severe ineffective immune activation
characterized by uncontrolled macrophage activity, cytokine hypersecretion, tissue infiltration by activated histiocytes and lymphocytes, and end-organ damage.18 It is a
heterogeneous group of disorders presenting with a myriad of clinical and laboratory findings including fever,
cytopenias, hyperferritinemia, hepatosplenomegaly, and
coagulopathy. There are many challenges in diagnosing
HLH; it is a rare disease entity with variable presentation
and nonspecific findings.19 The available HLH-2004 diagnostic criteria were used initially for pediatric HLH5;
these criteria are used, although they have not been validated, to diagnose adult HLH. The prognosis of adult
HLH is poor with early mortality reaching 44%.20
HLH is divided into primary (associated with inherited immune disorders) and secondary (associated with
infections, autoimmune disorders, malignancy) HLH.
Transplant-related HLH has been recognized as one of
the uncommon categories of secondary HLH.21 HLH following liver transplantation is rare and associated with
high mortality.22 In a recent review of the literature,
13 adult patients with secondary HLH following liver
transplantation were identified. Only two patients survived. Treatment was not standardized; however, the
authors recommended treatment of the underlying trigger and using high-dose intravenous steroids to control
the systemic inflammation.22
Although the risk of GVHD following liver transplant
is low, studies have shown that the liver allograft could
contain approximately the same number of donorderived WBCs as in peripheral stem cell infusions.23
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However, donor liver lymphocytes are distinct from those
in stem cell grafts with a higher percentage of CD8+ cells
and a reversed ratio of CD4:CD8 lymphocytes.24 Despite
the substantial differences between allogeneic stem cell
transplantation and liver transplantation and their distinct lymphocyte population, the pathogenesis of GVHD
in both instances is similar requiring viable T lymphocytes evading the host immune system and attacking different organs (except for the marrow which is spared in
allogeneic stem cell transplantation). Our patient developed GVHD and HLH following liver transplantation. He
was managed with ECP in combination with immunosuppressive therapy and etanercept. The role of ECP in
HLH and GVHD following liver transplantation has not
been defined or categorized by the most recent ASFA
guidelines.4 However, ECP is one of the standard treatments for acute GVHD following allogeneic stem cell
transplantation; this prompted us to start ECP for our
patient and continue with the same ECP protocol used in
managing GVHD following stem cell transplantation.
Knowing that GVHD following both allogeneic stem cell
transplantation and liver transplantation has the same
pathogenesis, it is reasonable to hypothesize that ECP
might be effective in liver transplant GVHD as it has
been proven to be effective in GVHD following allogeneic
stem cell transplantation.
Etanercept (TNF inhibitor) was also used in managing our patient. Although it is more commonly used in
managing GVHD following allogeneic stem cell transplantation, etanercept has been reported to be effective in
acute GVHD following liver transplantation.25 To the
best of our knowledge, this is the first case report of both
complications (i.e., GVHD and HLH) developing after
liver transplantation. What makes this case more interesting is the good outcome reached despite the fact that
both GVHD and HLH are known to be associated with
dismal prognosis. At one year follow-up, the patient is
doing well without evidence of GVHD or HLH.

4 | CONCLUSION
The occurrence of GVHD and HLH following liver transplantation is rare and portends poor prognosis. ECP in
combination with immunosuppressive therapy and etanercept was safe and efficient in managing GVHD and
HLH post liver transplantation in our patient. We do not
know if the early initiation of ECP treatment have contributed to the good outcome; this is worth investigating
in a large cohort study.
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